Epidemiological Evidence Between Variants in Matrix Metalloproteinases-2, -7, and -9 and Cancer Risk

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 May 16

PMID 35574300

Authors

Chenglu Huang

Suqin Xu

Zhilin Luo

Dong Li

Rui Wang

Tianhu Wang

Affiliations

Soon will be listed here.

Abstract

Background: Matrix metalloproteinases (s), a kind of proteases, have a critical function in cancer occurrence, invasion, and migration. gene variants (e.g., , , and ) can affect the biological functions of these enzymes and lead to the occurrence and progression of cancer, which has become a hot topic in recent years, but the corresponding results are still controversial. In this context, here, the meta-analysis was conducted for assessing the relations of variants in , , and with the risk of various cancers.

Methods: PubMed, Web of Science, and Medline were systemically searched, and data were extracted from all eligible studies so as to investigate the susceptibility of , , and to different types of cancers. The association between a variant in and cancer susceptibility was analyzed through odds ratios (ORs) as well as 95% CIs. The Venice criteria and false-positive report probability (FPRP) were adopted to evaluate epidemiological evidence of significant associations discovered.

Results: The associations between the variants of s and cancer risk in 36,530 cases and 41,258 controls were found, with 12 associations ( rs243865 with esophageal cancer and lung cancer, rs11568818 with bladder and cervical cancer, and rs3918242 with breast cancer) rated as strong associations for cancer risk and 7 and 15 as moderate and weak associations, respectively. These significant associations were mostly found in Asians.

Conclusions: These findings support the relations between variants of , , and and various cancers risk, demonstrating the credibility of these relations.

Citing Articles

Tumor-associated macrophages in bladder cancer: roles and targeted therapeutic strategies.

Ma Y, Sun Y, Guo H, Yang R Front Immunol. 2024; 15:1418131.

PMID: 39606239 PMC: 11599180. DOI: 10.3389/fimmu.2024.1418131.

The molecular characteristics could supplement the staging system of pT2/T3N0M0 esophageal squamous cell carcinoma: a translational study based on a cohort with over 20 years of follow-up.

Jiang W, Tian J, Guo Y, Qiu L, Luo X, Huang Y Cancer Cell Int. 2024; 24(1):119.

PMID: 38553712 PMC: 10981364. DOI: 10.1186/s12935-024-03286-5.

PLCD3 promotes malignant cell behaviors in esophageal squamous cell carcinoma via the PI3K/AKT/P21 signaling.

Wang M, Gao M, Chen Y, Wu J, Wang X, Shu Y BMC Cancer. 2023; 23(1):921.

PMID: 37773107 PMC: 10542242. DOI: 10.1186/s12885-023-11409-w.

The potential of epigallocatechin gallate in the chemoprevention and therapy of hepatocellular carcinoma.

Li D, Cao D, Cui Y, Sun Y, Jiang J, Cao X Front Pharmacol. 2023; 14:1201085.

PMID: 37292151 PMC: 10244546. DOI: 10.3389/fphar.2023.1201085.

Does the functional polymorphism-1562C/T of MMP-9 gene influence brain disorders?.

Pabian-Jewula S, Rylski M Front Cell Neurosci. 2023; 17:1110967.

PMID: 37206663 PMC: 10188926. DOI: 10.3389/fncel.2023.1110967.

References

Hua H, Li M, Luo T, Yin Y, Jiang Y . Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci. 2011; 68(23):3853-68. PMC: 11114831. DOI: 10.1007/s00018-011-0763-x. View

Rahimi Z, Rahimi Z, Shahsavandi M, Bidoki K, Rezaei M . MMP-9 (-1562 C:T) polymorphism as a biomarker of susceptibility to severe pre-eclampsia. Biomark Med. 2013; 7(1):93-8. DOI: 10.2217/bmm.12.95. View

Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N . Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004; 96(6):434-42. PMC: 7713993. DOI: 10.1093/jnci/djh075. View

Wu Z, Jiang P, Zulqarnain H, Gao H, Zhang W . Relationship between single-nucleotide polymorphism of matrix metalloproteinase-2 gene and colorectal cancer and gastric cancer susceptibility: a meta-analysis. Onco Targets Ther. 2015; 8:861-9. PMC: 4406259. DOI: 10.2147/OTT.S78031. View

Peng B, Cao L, Ma X, Wang W, Wang D, Yu L . Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk. Mutagenesis. 2010; 25(4):371-9. DOI: 10.1093/mutage/geq015. View

Singh N, Hussain S, Sharma U, Suri V, Nijhawan R, Bharadwaj M . The protective role of the -1306C>T functional polymorphism in matrix metalloproteinase-2 gene is associated with cervical cancer: implication of human papillomavirus infection. Tumour Biol. 2015; 37(4):5295-303. DOI: 10.1007/s13277-015-4378-y. View

Rahimi Z, Rahimi Z, Aghaei A, Vaisi-Raygani A . AT2R -1332 G:A polymorphism and its interaction with AT1R 1166 A:C, ACE I/D and MMP-9 -1562 C:T polymorphisms: risk factors for susceptibility to preeclampsia. Gene. 2014; 538(1):176-81. DOI: 10.1016/j.gene.2013.12.013. View

Yamashita K, Upadhay S, Mimori K, Inoue H, Mori M . Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer. 2003; 97(10):2412-9. DOI: 10.1002/cncr.11368. View

Chen G, Wang S, Shen T, Tsai C, Chang W, Li H . The association of matrix metalloproteinas-2 promoter polymorphisms with lung cancer susceptibility in Taiwan. Chin J Physiol. 2019; 62(5):210-216. DOI: 10.4103/CJP.CJP_43_19. View

10.

Mao F, Niu X, Gu S, Ji L, Wei B, Wang H . The association between matrix metalloproteinase-7 genetic variant and bladder cancer risk in a Chinese Han population. Clin Exp Med. 2019; 19(4):565-570. DOI: 10.1007/s10238-019-00582-7. View

11.

Przybylowska K, Kluczna A, Zadrozny M, Krawczyk T, Kulig A, Rykala J . Polymorphisms of the promoter regions of matrix metalloproteinases genes MMP-1 and MMP-9 in breast cancer. Breast Cancer Res Treat. 2005; 95(1):65-72. DOI: 10.1007/s10549-005-9042-6. View

12.

Wilson C, Matrisian L . Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol. 1996; 28(2):123-36. DOI: 10.1016/1357-2725(95)00121-2. View

13.

Zhang L, Xi R, Zhang X . Matrix metalloproteinase variants associated with risk and clinical outcome of esophageal cancer. Genet Mol Res. 2015; 14(2):4616-24. DOI: 10.4238/2015.May.4.20. View

14.

Waleh N, Murphy B, Zaveri N . Increase in tissue inhibitor of metalloproteinase-2 (TIMP-2) levels and inhibition of MMP-2 activity in a metastatic breast cancer cell line by an anti-invasive small molecule SR13179. Cancer Lett. 2009; 289(1):111-8. DOI: 10.1016/j.canlet.2009.08.006. View

15.

Mattiuzzi C, Lippi G . Current Cancer Epidemiology. J Epidemiol Glob Health. 2019; 9(4):217-222. PMC: 7310786. DOI: 10.2991/jegh.k.191008.001. View

16.

Kessenbrock K, Plaks V, Werb Z . Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010; 141(1):52-67. PMC: 2862057. DOI: 10.1016/j.cell.2010.03.015. View

17.

Decock J, Paridaens R, Ye S . Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clin Genet. 2008; 73(3):197-211. DOI: 10.1111/j.1399-0004.2007.00946.x. View

18.

Bourboulia D, Han H, Jensen-Taubman S, Gavil N, Isaac B, Wei B . TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cells. Oncotarget. 2013; 4(1):166-76. PMC: 3702216. DOI: 10.18632/oncotarget.801. View

19.

Eftekhary H, Ziaee A, Yazdanbod M, Shahpanah M, Setayeshgar A, Nassiri M . The influence of matrix metalloproteinase-2, -9, and -12 promoter polymorphisms on Iranian patients with oesophageal squamous cell carcinoma. Contemp Oncol (Pozn). 2015; 19(4):300-5. PMC: 4631297. DOI: 10.5114/wo.2015.48569. View

20.

Deryugina E, Quigley J . Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. Matrix Biol. 2015; 44-46():94-112. PMC: 5079283. DOI: 10.1016/j.matbio.2015.04.004. View